Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-30 · accession 0000899243-23-000237 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-03 | 2022-12-30 | BEAM | Ciaramella Giuseppe | Pres, CSO | M - OptEx | $0.67 | +4,500 | 96.0K | +5% | +$3,015 |
| D | 2023-01-03 | 2022-12-30 | BEAM | Ciaramella Giuseppe | Pres, CSO | M - OptEx | $0.00 | -4,500 | 191.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | M | A | 4,500 | $0.67 | 95,962 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-30 | M | D | 4,500 | $0.00 | 191,202 | D | $0.67 · — to 2028-05-08 | 4,500 Common Stock | (F2) On April 2, 2021, the reporting person filed a Form 4 which inadvertently reported in column 9 that, following his exercise of an option, the number of derivative securities beneficially owned was 265,414 shares, when this number should have been reported as 253,414 shares. This Form 4 reflects the corrected number of derivative securities beneficially owned following the transactions reported since April 2, 2021, including the transaction reported herein. (F1) The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter. |